Abstract
Polyglutamine diseases are hereditary neurodegenerative disorders caused by the expansion of a CAG repeat in the disease gene. A dominant gain of function is associated with these expanded alleles. The resulting elongated polyglutamine repeats are thought to cause structural changes in the affected proteins, leading to aberrant interactions such as those that allow formation of extra- and intranuclear aggregates. However, self-association is not the only interaction the polyglutamine domain is capable of mediating. Many cellular proteins can be sequestered into inclusions or bound by more soluble forms of the mutant proteins. One group of proteins that binds to and whose activity may be altered by polyglutamines is Histone Acetyltransferases (HATs). HATs are responsible for the acetylation of histones and several other important proteins and this modification results in altered function of the target protein. HATs regulate cellular processes at levels as different as modifying transcriptional competence of chromosomes, temporal regulation of promoter activity and protein activation / inactivation. Recent studies show that the altered balance between protein acetylation and deacetylation may be a key process contributing to expanded polyglutamine-induced pathogenesis. The restoration of this balance is possible by the genetic or pharmacological reduction of the opposing enzyme group, i.e. the Histone Deacetylases (HDACs). Recent progress in HDAC research has made the development of inhibitors of specific HDAC family proteins possible and these compounds could be effective candidates for treatment of these devastating diseases.
Keywords: polyglutamine diseases, polyq, huntington's disease, neurodegeneration, protein acetylation, hat, hdac, hdac inhibitors
Current Medicinal Chemistry
Title: [General Articles] Altered Protein Acetylation in Polyglutamine Diseases
Volume: 10 Issue: 23
Author(s): L. Bodai, J. Pallos, L. M. Thompson and J. L. Marsh
Affiliation:
Keywords: polyglutamine diseases, polyq, huntington's disease, neurodegeneration, protein acetylation, hat, hdac, hdac inhibitors
Abstract: Polyglutamine diseases are hereditary neurodegenerative disorders caused by the expansion of a CAG repeat in the disease gene. A dominant gain of function is associated with these expanded alleles. The resulting elongated polyglutamine repeats are thought to cause structural changes in the affected proteins, leading to aberrant interactions such as those that allow formation of extra- and intranuclear aggregates. However, self-association is not the only interaction the polyglutamine domain is capable of mediating. Many cellular proteins can be sequestered into inclusions or bound by more soluble forms of the mutant proteins. One group of proteins that binds to and whose activity may be altered by polyglutamines is Histone Acetyltransferases (HATs). HATs are responsible for the acetylation of histones and several other important proteins and this modification results in altered function of the target protein. HATs regulate cellular processes at levels as different as modifying transcriptional competence of chromosomes, temporal regulation of promoter activity and protein activation / inactivation. Recent studies show that the altered balance between protein acetylation and deacetylation may be a key process contributing to expanded polyglutamine-induced pathogenesis. The restoration of this balance is possible by the genetic or pharmacological reduction of the opposing enzyme group, i.e. the Histone Deacetylases (HDACs). Recent progress in HDAC research has made the development of inhibitors of specific HDAC family proteins possible and these compounds could be effective candidates for treatment of these devastating diseases.
Export Options
About this article
Cite this article as:
Bodai L., Pallos J., Thompson M. L. and Marsh L. J., [General Articles] Altered Protein Acetylation in Polyglutamine Diseases, Current Medicinal Chemistry 2003; 10 (23) . https://dx.doi.org/10.2174/0929867033456530
DOI https://dx.doi.org/10.2174/0929867033456530 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Probing Cerebrovascular Alterations in Alzheimers Disease Using MRI: From Transgenic Models to Patients
Current Medical Imaging The Intracellular Domain of Amyloid Precursor Protein is a Potential Therapeutic Target in Alzheimer’s Disease
Current Drug Discovery Technologies Increase of EEG Alpha3/Alpha2 Power Ratio Detects Inferior Parietal Lobule Atrophy in Mild Cognitive Impairment
Current Alzheimer Research Editorial (Thematic Issue: Old Facts and New Perspectives to Face Alzheimer’s Dementia. Focus on Non Neuronal Participants to Neurodegeneration)
CNS & Neurological Disorders - Drug Targets Biochemical and Therapeutic Effects of Antioxidants in the Treatment of Alzheimers Disease, Parkinsons Disease, and Amyotrophic Lateral Sclerosis
Current Drug Targets - CNS & Neurological Disorders Neuroprotective Properties of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) and its Lipid Ligands
Current Medicinal Chemistry Activated Immune System and Inflammation in Healthy Ageing: Relevance for Tryptophan and Neopterin Metabolism
Current Pharmaceutical Design Editorial: In Silico Studies in Drug Research Against Neurodegenerative Diseases
Current Neuropharmacology Patent Selections
Recent Patents on Biomarkers Transgenic Mouse Models of Alzheimer Disease: Developing a Better Model as a Tool for Therapeutic Interventions
Current Pharmaceutical Design Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer’s Disease
Current Medicinal Chemistry New Emerging Trends in Protein and Peptide Based Therapeutic Approaches – Part I
Current Protein & Peptide Science Neuroactive Molecules in the Brains of Nonhuman Primates and Their Therapeutic Application to Neurodegenerative Disorders
Central Nervous System Agents in Medicinal Chemistry Brain Oxidative Stress - Analytical Chemistry and Thermodynamics of Glutathione and NADPH
Current Topics in Medicinal Chemistry Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry On the Search for Skin Gene Therapy Strategies of Xeroderma Pigmentosum Disease
Current Gene Therapy Responses of Glial Cells to Stress and Glucocorticoids
Current Immunology Reviews (Discontinued) Molecular Biomarkers for Amyotrophic Lateral Sclerosis
Current Bioinformatics Novel Lactulose and Melibiose Targeting Autophagy to Reduce PolyQ Aggregation in Cell Models of Spinocerebellar Ataxia 3
CNS & Neurological Disorders - Drug Targets High Glucose Enhances Neurotoxicity and Inflammatory Cytokine Secretion by Stimulated Human Astrocytes
Current Alzheimer Research